CTXR Citius Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CTXR
Price (delayed)
$1.34
Market cap
$22.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.09
Enterprise value
$18.55M
Relative Growth:
Rel. Growth:
14
Relative Strength:
Rel. Strength:
26
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
7
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Highlights
The EPS is up by 18% year-on-year and by 13% since the previous quarter
Citius Pharmaceuticals's equity has decreased by 24% YoY but it has increased by 7% QoQ
The net income is down by 5% year-on-year but it is up by 4.2% since the previous quarter
CTXR's debt has soared by 102% QoQ
Citius Pharmaceuticals's quick ratio has shrunk by 97% YoY
Key stats
What are the main financial stats of CTXR
Market
Valuations
Earnings
Shares outstanding
17.01M
Market cap
$22.8M
Enterprise value
$18.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$41.14M
Net income
-$40.26M
EBIT
-$39.16M
EBITDA
-$38.95M
Free cash flow
-$20.58M
Per share
Balance sheet
Liquidity
EPS
-$5.09
EPS diluted
-$5.09
Free cash flow per share
-$1.87
Book value per share
$6.32
Revenue per share
$0
TBVPS
$10.75
Total assets
$127.68M
Total liabilities
$60.12M
Debt
$1.88M
Equity
$65.06M
Working capital
-$27.23M
Debt to equity
0.03
Current ratio
0.47
Quick ratio
0.12
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.7%
Return on equity
-62.8%
Return on invested capital
-60.4%
Return on capital employed
-51.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTXR stock price
How has the Citius Pharmaceuticals stock price performed over time
Intraday
-2.19%
1 week
-14.65%
1 month
0.75%
1 year
-84.56%
YTD
-66.5%
QTD
8.06%
Financial performance
How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.14M
Net income
-$40.26M
Gross margin
N/A
Net margin
N/A
The net income is down by 5% year-on-year but it is up by 4.2% since the previous quarter
The operating income rose by 4.3% QoQ
Price vs fundamentals
How does CTXR's price correlate with its fundamentals
Growth
What is Citius Pharmaceuticals's growth rate over time
Valuation
What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 85% lower than the 5-year quarterly average of 1.5 and 63% lower than the last 4 quarters average of 0.6
Citius Pharmaceuticals's equity has decreased by 24% YoY but it has increased by 7% QoQ
Efficiency
How efficient is Citius Pharmaceuticals business performance
CTXR's ROE is down by 34% YoY and by 2.6% from the previous quarter
The company's return on assets rose by 18% YoY and by 11% QoQ
The ROIC has grown by 3.7% from the previous quarter but it has contracted by 2.4% YoY
Dividends
What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTXR.
Financial health
How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's total assets is 112% higher than its total liabilities
Citius Pharmaceuticals's quick ratio has shrunk by 97% YoY
Citius Pharmaceuticals's current ratio has shrunk by 93% YoY but it has increased by 27% QoQ
CTXR's debt is 97% lower than its equity
CTXR's debt has soared by 102% QoQ
The debt to equity has soared by 50% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.